www.fdanews.com/articles/166400-mirati-therapeutics-receives-orphan-designation-from-us-food-drug-administration-for-mocetinostat-in-diffuse-large-b-cell-lymphoma

Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma

August 11, 2014

Mirati Therapeutics announced that the FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL).
Yahoo Finance